Statin use and the risk of Alzheimer’s disease: The MIRAGE Study

Statin use and the risk of Alzheimer’s disease: The MIRAGE Study

The aim of this study was to examine the association between statin use before the onset of Alzheimer’s disease (AD) symptoms and risk of having AD, and to explore the potential impact of APOE genotype and race on this association. Data were collected through standardized, validated questionnaires f...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's & dementia Vol. 2; no. 2; pp. 96 - 103
Main Authors: Green, Robert C., McNagny, Sally E., Jayakumar, Parimala, Cupples, L. Adrienne, Benke, Kelly, Farrer, Lindsay A.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-04-2006
Subjects:
Alzheimer
Cholesterol
Dementia
Epidemiology
Lipids
Risk
Statin
Lipids
Risk
Statin
Alzheimer
Epidemiology
Cholesterol
Dementia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to examine the association between statin use before the onset of Alzheimer’s disease (AD) symptoms and risk of having AD, and to explore the potential impact of APOE genotype and race on this association. Data were collected through standardized, validated questionnaires from 895 subjects with probable or definite AD by research criteria, and 1,483 of their nondemented relatives in this family-based, case-control study of AD patients and their relatives enrolled at 15 research centers from 1996 through 2002. To minimize temporal and prescription biases, exposure to statin use within each family was ignored in the one year before the first appearance of AD symptoms in that family’s affected member. Associations were estimated using generalized estimating equations for a logistic model, adjusting for age, sex, race, education, history of heart disease, stroke, diabetes, smoking and APOE genotype. Statin use was associated with lowered odds of having AD (adjusted odds ratio [OR], 0.61; 95% confidence interval [CI], 0.38 to 0.98). Nonstatin cholesterol-lowering medications were not associated significantly with lowered odds of having had AD (adjusted OR, 1.7; 95% CI, 0.61 to 5.0). Statin medications were associated with lowered risk of AD in this population. Neither African-American race, nor the presence of the APOE ϵ4 allele modified the statin-AD association.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1552-5260
1552-5279
DOI:10.1016/j.jalz.2006.02.003